The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.130.6.670

Empirical studies of the treatment of schizophrenia show the unequivocal ameliorative effects of psychoactive drugs. No comparable effects have been claimed for psychotherapy. As a result, psychotherapy has tended to be negated as a viable therapeutic factor in the treatment of schizophrenia. Yet the sophisticated drug evaluation studies are not matched by sophisticated assessments of psychotherapy. Serious methodological errors exist in the latter studies; there have been inappropriate outcome criteria, inadequate assessment procedures to measure change, unsound selection of therapists, and unclear diagnostic appraisals. The issue has been further clouded by the heterogeneous nature of psychotherapeutic interventions, comprising as they do—in contrast to the relatively simple administration of drugs—a congeries of methods, techniques, and goals. This paper examines some of the requirements for appropriate evaluation studies of psychotherapy of schizophrenic patients.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.